Kloeckner Lifts Forecast For Q3, FY21 Adj. EBITDA; Stock Up

Shares of Kloeckner & Co SE (KCO) were gaining around 7 percent in German trading after the steel and metal distributor Monday lifted its adjusted EBITDA forecast for the third quarter and fiscal 2021.

The company said it expects fiscal 2021 operating income to be even stronger.

For the third quarter, the company now expects adjusted operating income or EBITDA of 260 million euros to 280 million euros, higher than previously expected 200 million euros to 230 million euros.

The company noted that the positive dynamics of steel prices, particularly in the US, continued during the third quarter.

The outlook revision reflects the development in the steel price and the continued extremely strict net working capital management.

Further ahead, Kloeckner now expects to fiscal 2021 adjusted EBITDA of around 800 million euros, higher than previous forecast of 650 million euros to 700 million euros.

The company expects this to be its best operating full-year income since its IPO in 2006.

The third-quarter results will be announced on November 3.

In Germany, Kloeckner shares were trading at 10.58 euros, up 6.71 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Frozen Food Development is recalling specific lots of Lidl branded 12-ounce packages of Frozen Chopped Spinach citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The product comes in 12-ounce poly bags, and items included in the recall are marked with lot # R17742 or R17963 on the back of the poly bag with a best by date of 09/10/23. Starbucks has dropped its vaccine or weekly test requirement against Covid-19 for U.S. employees in the wake of last week's U.S. Supreme Court ruling. The court, in a 6-3 vote, has blocked President Joe Biden's vaccine-or-test mandate for private companies with 100 or more employees. However, it allowed the vaccine mandate to stand for certain health care workers. Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling one batch of its non-interchangeable Semglee (insulin glargine injection), 100 units/ml (U-100), 3mL prefilled pens due to the potential for a missing label, the U.S. Food and Drug Administration said.
Follow RTT